当前位置:
X-MOL 学术
›
Lancet Oncol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
60th ASTRO Annual Meeting
The Lancet Oncology ( IF 41.6 ) Pub Date : 2018-10-25 , DOI: 10.1016/s1470-2045(18)30818-0
Cheryl Lai
The Lancet Oncology ( IF 41.6 ) Pub Date : 2018-10-25 , DOI: 10.1016/s1470-2045(18)30818-0
Cheryl Lai
![]() |
Daniel Gomez (MD Anderson Cancer Center, Houston, TX, USA) presented the final results of a randomised, phase 2 trial in which patients with stage IV non-small-cell lung cancer with oligometastases were randomly assigned to receive local consolidative therapy (chemoradiotherapy or resection) followed by subsequent standard maintenance treatment/observation or to standard maintenance treatment/observation alone. The primary endpoint of progression-free survival was previously reported to be improved with local consolidative therapy. In this final analysis, at a median follow-up of 38·8 months (range 28·3–61·4), overall survival was significantly longer in patients in the local consolidative therapy group than in the control group (median overall survival 41·2 months [95% CI 18·9–not reached] vs 17.0 months [10·1–39·8]; p=0·017). No additional grade 3 or worse adverse events were reported.
中文翻译:
ASTRO第60届年会
Daniel Gomez(美国得克萨斯州休斯顿的MD安德森癌症中心)介绍了一项随机的2期试验的最终结果,该试验将IV期非小细胞肺癌低聚转移患者随机分配接受局部巩固治疗(放化疗)或切除),然后进行后续的标准维护治疗/观察或仅进行标准维护治疗/观察。先前报道无进展生存的主要终点是通过局部巩固疗法得到改善。在此最终分析中,在中位随访期38·8个月(范围28·3–61·4)中,局部巩固治疗组患者的总生存期显着长于对照组(中位总体生存期41 ·2个月[95%CI 18·9 –未达到]与17.0个月[10·1–39·8];p = 0·017)。尚无其他3级或更严重不良事件的报道。
更新日期:2018-11-29
中文翻译:

ASTRO第60届年会
Daniel Gomez(美国得克萨斯州休斯顿的MD安德森癌症中心)介绍了一项随机的2期试验的最终结果,该试验将IV期非小细胞肺癌低聚转移患者随机分配接受局部巩固治疗(放化疗)或切除),然后进行后续的标准维护治疗/观察或仅进行标准维护治疗/观察。先前报道无进展生存的主要终点是通过局部巩固疗法得到改善。在此最终分析中,在中位随访期38·8个月(范围28·3–61·4)中,局部巩固治疗组患者的总生存期显着长于对照组(中位总体生存期41 ·2个月[95%CI 18·9 –未达到]与17.0个月[10·1–39·8];p = 0·017)。尚无其他3级或更严重不良事件的报道。